Alto Neuroscience, Inc.
ANRO
$34.18
-$1.63-4.55%
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.59% | 35.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.34% | 59.12% | |||
| Operating Income | -7.34% | -59.12% | |||
| Income Before Tax | -5.34% | -62.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.34% | -62.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.34% | -62.14% | |||
| EBIT | -7.34% | -59.12% | |||
| EBITDA | -7.39% | -59.51% | |||
| EPS Basic | 19.06% | -68.48% | |||
| Normalized Basic EPS | 19.06% | -68.47% | |||
| EPS Diluted | 19.06% | -68.48% | |||
| Normalized Diluted EPS | 19.06% | -68.47% | |||
| Average Basic Shares Outstanding | 30.16% | -3.77% | |||
| Average Diluted Shares Outstanding | 30.16% | -3.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||